Document is current
Any future updates will be listed below
-
Authors
Dubler, S. https://orcid.org/0000-0003-0886-595X
Lenz, M.
Zimmermann, S.
Richter, D. C.
Weiss, K. H.
Mehrabi, A.
Mieth, M.
Bruckner, T.
Weigand, M. A.
Brenner, T.
Heininger, A.
- License Information
-
More Information
Article History
Received: 25 November 2019
Accepted: 22 January 2020
First Online: 31 January 2020
Ethics approval and consent to participate
: Ethics approval by the local ethics committee of the Medical Faculty of the University of Heidelberg, Germany (S-407/2017) and was registered at the German clinical trials register (DRKS-ID: DRKS00013285).
: Not applicable.
: Karl-Heinz Weiss advises for Alexion, Univar, GMP-O, Ipsen, Chiesi, Novartis. Karl-Heinz Weiss is on the speaker’s bureau of Pfizer, Abbvie, Eisai. Karl-Heinz Weiss received grant support (to the institution) from AstraZenica, QED, Novartis, Univar, Alexion and GMP-O. Markus Weigand is on the advisory boards from MSD, Gilead, Pfizer, Shionogi. Thorsten Brenner received research funding from German Research Foundation (DFG), Heidelberg Foundation of Surgery, Dietmar Hopp Foundation. Thorsten Brenner received honoraria for lectures and advisory boards from: Biotest AG, Baxter Deutschland GmbH, Schöchl medical education GmbH, Boehringer Ingelheim Pharma GmbH, CSL Behring GmbH, Astellas Pharma GmbH, B. Braun Melsungen AG, MSD Sharp & Dohme GmbH. Alexandra Heininger received speaker honorary by MSD and Pfizer. Simon Dubler, Martin Lenz, Stefan Zimmermann, Daniel Richter, Arianeb Mehrabi, Markus Mieth and Thomas Brucker declare that they have no competing interests.
